Genentech and AC Immune have announced a $300 million licensing agreement relating to the development of antibodies
for treating Alzheimer's disease. AC
Immune's research in the Alzheimer's area includes inducing anti-beta amyloid
antibody production in patients. The
announcement marks the third recent major licensing deal between Genentech and
a
partner whose research focuses on a particular therapeutic area, including an
October deal with CGI Pharmaceuticals ($500 million deal relating to cancer and immune diseases) and a July deal with
Inotek Pharmaceuticals ($405 million deal relating to cancer treatment).
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments